Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.

Ajai Chari; Robert F. Cornell; Cristina Gasparetto; Chatchada Karanes; Jeffrey V. Matous; Ruben Niesvizky; Matthew Lunning; Saad Z. Usmani; Larry D. Anderson; Saurabh Chhabra; Saulius Girnius; Chaim Shustik; Robert Stuart; Yihua Lee; Zeena Salman; Emily Liu; Jason Valent

doi:10.1002/HON.2723

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.

Ajai Chari
, Robert F. Cornell
, Cristina Gasparetto
, Chatchada Karanes
, Jeffrey V. Matous
, Ruben Niesvizky
, Matthew Lunning
, Saad Z. Usmani
, Larry D. Anderson
, Saurabh Chhabra
, Saulius Girnius
, Chaim Shustik
, Robert Stuart
, Yihua Lee
, Zeena Salman
, Emily Liu
, Jason Valent

Icahn School of Medicine at Mount Sinai
Vanderbilt University Medical Center
Duke University
City of Hope National Medical Center
Department of Hematology/Oncology, Colorado Blood Cancer Institute, Denver, Colorado
Cornell University
University of Nebraska Medical Center
Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
University of Texas Southwestern Medical Center
Medical College of Wisconsin
University of Cincinnati
McGill University Health Centre
Medical University of South Carolina
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.
Cleveland Clinic

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Hematological Oncology
Volume	38
Issue number	3
DOIs	https://doi.org/10.1002/HON.2723
State	Published - Feb 13 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1002/HON.2723License: Unspecified

Cite this

Chari, A., Cornell, R. F., Gasparetto, C., Karanes, C., Matous, J. V., Niesvizky, R., Lunning, M., Usmani, S. Z., Anderson, L. D., Chhabra, S., Girnius, S., Shustik, C., Stuart, R., Lee, Y., Salman, Z., Liu, E., & Valent, J. (2020). Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematological Oncology, 38(3). https://doi.org/10.1002/HON.2723

Chari, A, Cornell, RF, Gasparetto, C, Karanes, C, Matous, JV, Niesvizky, R, Lunning, M, Usmani, SZ, Anderson, LD, Chhabra, S, Girnius, S, Shustik, C, Stuart, R, Lee, Y, Salman, Z, Liu, E & Valent, J 2020, 'Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.', Hematological Oncology, vol. 38, no. 3. https://doi.org/10.1002/HON.2723

@article{a5079ea6f1f24d0a890dcacadc052054,

title = "Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.",

author = "Ajai Chari and Cornell, \{Robert F.\} and Cristina Gasparetto and Chatchada Karanes and Matous, \{Jeffrey V.\} and Ruben Niesvizky and Matthew Lunning and Usmani, \{Saad Z.\} and Anderson, \{Larry D.\} and Saurabh Chhabra and Saulius Girnius and Chaim Shustik and Robert Stuart and Yihua Lee and Zeena Salman and Emily Liu and Jason Valent",

note = "Ajai Chari, 1 Robert F. Cornell, 2 Cristina Gasparetto, 3 Chatchada Karanes, 4 Jeffrey V. Matous, 5 Ruben Niesvizky, 6 Matthew Lunning, 7 Saad Z. Usmani, 8 Larry D.",

year = "2020",

month = feb,

day = "13",

doi = "10.1002/HON.2723",

language = "American English",

volume = "38",

journal = "Hematological Oncology",

issn = "1099-1069",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.

AU - Chari, Ajai

AU - Cornell, Robert F.

AU - Gasparetto, Cristina

AU - Karanes, Chatchada

AU - Matous, Jeffrey V.

AU - Niesvizky, Ruben

AU - Lunning, Matthew

AU - Usmani, Saad Z.

AU - Anderson, Larry D.

AU - Chhabra, Saurabh

AU - Girnius, Saulius

AU - Shustik, Chaim

AU - Stuart, Robert

AU - Lee, Yihua

AU - Salman, Zeena

AU - Liu, Emily

AU - Valent, Jason

N1 - Ajai Chari, 1 Robert F. Cornell, 2 Cristina Gasparetto, 3 Chatchada Karanes, 4 Jeffrey V. Matous, 5 Ruben Niesvizky, 6 Matthew Lunning, 7 Saad Z. Usmani, 8 Larry D.

PY - 2020/2/13

Y1 - 2020/2/13

UR - https://europepmc.org/article/MED/32053229

U2 - 10.1002/HON.2723

DO - 10.1002/HON.2723

M3 - Article

SN - 1099-1069

VL - 38

JO - Hematological Oncology

JF - Hematological Oncology

IS - 3

ER -

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.

Disciplines

Access to Document

Other files and links

Cite this